2016 News Releases

Webcast ImageWebcast
Neuralstem, Inc at BIO CEO & Investor Conference (Replay)
02/13/17 at 8:30 a.m. ET
Webcast ImageWebcast
Neuralstem, Inc. at 29th Annual ROTH Conference (Replay)
03/13/17 at 12:00 p.m. PT
Webcast ImageWebcast
Neuralstem, Inc. at Oppenheimer 27th Annual Healthcare Conference (Replay)
03/21/17 at 1:00 p.m. ET
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/12/16Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.
GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announces the closing of Tianjin Pharmaceutical Group International Holdings Co., LTD.’s (TJPH or Tianjin) $20 million strategic investment. Upon the close of the transaction, Tianjin receives 28,500,000 shares of common stock and 1,000,000 shares of Series A convertible preferred s... 
Download PDFPrinter Friendly Version
11/08/16Neuralstem Reports Third Quarter 2016 Results
Provides Business and Clinical Updates GERMANTOWN, Md., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results and provided business and clinical updates for the three and nine month periods ended September 30, 2016. “This is an exciting time for Neuralstem, as we successfully continue to execute the new operational an... 
Download PDFPrinter Friendly Version
11/02/16Neuralstem  Announces Presentations at Upcoming Scientific Conferences
GERMANTOWN, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced poster presentations at two upcoming scientific conferences.  Presentations include preclinical data in both of the company’s stem cell and small molecule platforms at the Society for Neurosciences Annual Meeting, as well as the American College of Toxicology Annual Meetin... 
Download PDFPrinter Friendly Version
10/20/16Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits at the Radiation Research Society Annual Meeting
NSI-189 Shows Reversal of Radiation-induced Cognitive Deficits GERMANTOWN, Md., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced the presentation of the poster entitled, “Reversal of radiation-induced cognitive impairment by oral administration of a neurogenic small molecule compound NSI-189,” at the Radiation Research Society Annual Me... 
Download PDFPrinter Friendly Version
09/21/16Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder
GERMANTOWN, Md., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that it has reached over 50% enrollment in its Phase 2 clinical trial evaluating NSI-189, a novel neurogenic small molecule, for the treatment of major depressive disorder (MDD). The ongoing Phase 2 MDD study is testing two doses (40mg QD and 40mg BID) of NSI-189, a sm... 
Download PDFPrinter Friendly Version
09/12/16Neuralstem Presented NSI-189 Preclinical Data in Type 1 and Type 2 Diabetes at the Annual Meeting of the Diabetic Neuropathy Study Group
NSI-189 Shows Prevention and Reversal of Diabetic Neuropathies in Mice GERMANTOWN, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell proprietary technology, announced that Karl Johe, Ph.D., Chief Scientific Officer, presented the poster, “Therapeutic Efficacy of NSI-189 in Diabetic Mice,” at the Annual Meeting of the Diabetic Neuropathy Study Group of t... 
Download PDFPrinter Friendly Version
09/12/16Neuralstem Receives $20,000,000 Strategic Investment from Tianjin Pharmaceutical Group
GERMANTOWN, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that on September 7, 2016, it entered into definitive agreements with Tianjin Pharmaceutical Holding Group for the private placement of common stock and convertible preferred stock for gross proceeds of $20,000,000. Neuralstem intends to use the net proceeds from th... 
Download PDFPrinter Friendly Version
08/11/16Neuralstem Reports Second Quarter 2016 Results and Provides Business and Clinical Updates
Dr. Karl Johe Resigns from Board of Directors; Company Announces Creation of Scientific Policy Committee with Dr. Johe as Chairman GERMANTOWN, Md., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results and provided business and clinical updates for the three and six months periods ended June 30, 2016. “During the quar... 
Download PDFPrinter Friendly Version
06/21/16Neuralstem Announces NSI-189 Shows Enhancement of Long-Term Potentiation In Vitro
Data Contribute to Understanding NSI-189 Mechanism of Action GERMANTOWN, Md., June 21, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that new in vitro data on NSI-189 provide insight into the neurogenic drug’s mode of action.  In a study entitled, “NSI-189, a neurogenic compound enhances short-term and long-term potentiation in C57Bl/6 mice a... 
Download PDFPrinter Friendly Version
06/13/16Neuralstem Announces New Chairman and Further Reorganization Plans
GERMANTOWN, Md., June 13, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced, in furtherance of its reorganization plans and focus on clinical development, that Richard Daly, the company’s president and chief executive officer, has been appointed chairman of the board of directors.  Mr. Daly’s appointment as chairman will allow Dr. Karl Johe,... 
Download PDFPrinter Friendly Version
05/20/16Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent
GERMANTOWN, Md., May 20, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced a corporate reorganization to further align the company's resources on advancing the NSI-189 neurogenic small molecule program, currently in a Phase 2 clinical trial for the treatment of major depressive disorder, and to continue to pursue collaborations for the NSI-566 stem cel... 
Download PDFPrinter Friendly Version
05/12/16Neuralstem to Raise $1.08 Million
GERMANTOWN, Md., May 12, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that it has entered into a definitive agreement to sell 2,700,000 shares of its common stock and warrants to purchase 2,700,000 shares of common stock in a private placement. The securities are being sold in a private offering at a price of $0.40 per one share of common st... 
Download PDFPrinter Friendly Version
05/12/16Neuralstem Announces First Patient Enrolled in Phase 2 Clinical Trial in Major Depressive Disorder
Trial Efficacy Endpoints Include Reduction in Depression and Cognition Improvement GERMANTOWN, Md., May 12, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that the first patient has been enrolled in the double-blind, placebo-controlled multi-center Phase 2 study of NSI-189 for the treatment of major depressive disorder (MDD). NSI-189, the lea... 
Download PDFPrinter Friendly Version
05/09/16Neuralstem Reports Fiscal First Quarter 2016 Results and Business Update
GERMANTOWN, Md., May 9, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results for the three months ended March 31, 2016 and provided a business update. Business Highlights On May 6, 2016, the Company closed a public offering resulting in net proceeds of $7.42 million.  The net proceeds will be used for general corporate purpose... 
Download PDFPrinter Friendly Version
05/03/16Neuralstem Prices Underwritten Public Offering of Securities
GERMANTOWN, Md., May 3, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $0.40 per share and warrants to purchase 20,000,000 shares of common stock.  The warrants have an exercise price of $0.40 per share, are immediately exercis... 
Download PDFPrinter Friendly Version
05/02/16Neuralstem Announces Proposed Public Offering of Securities
GERMANTOWN, Md., May 2, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.  The shares of common stock and warrants will be immediately separable and will be issued separately. All securities in the offering a... 
Download PDFPrinter Friendly Version
04/21/16Neuralstem Receives NASDAQ Notice of Bid Price Deficiency
GERMANTOWN, Md., April 21, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that on April 20, 2016 it received a written notice from the NASDAQ Stock Market LLC that the Company is not in compliance with NASDAQ Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business day... 
Download PDFPrinter Friendly Version
03/14/16Neuralstem Reports Fourth Quarter and Year End 2015 Fiscal Results and Business Update
FDA Approval to Commence Phase 2 Major Depressive Disorder Clinical Trial GERMANTOWN, Md., March 14, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results for the fourth quarter and year ended December 31, 2015. Clinical Program and Business Highlights Business Highlights The Company strengthened its executive team with the app... 
Download PDFPrinter Friendly Version
03/11/16Neuralstem's Preclinical Alzheimer's Disease Data Published In Stem Cells Translational Medicine - See more at: http://investor.neuralstem.com/press-releases?year=2016#sthash.MMyA86LN.dpuf
GERMANTOWN, Md., Jan. 11, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced publication of  "Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-1: A Novel Cellular Therapy for Alzheimer's Disease," in Stem Cells Translational Medicine (http://stemcellstm.alphamedpress.org/content/early/2016/01/07/sctm.2... 
Download PDFPrinter Friendly Version
03/10/16Neuralstem to Present at 28th Annual Roth Conference
GERMANTOWN, Md., March 10, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that it will present at the 28th Annual Roth Conference in Dana Point, CA on Tuesday, March 15, 2016.  The presentation is scheduled at 11:00AM PST. A live audio webcast of the presentation will be available by visiting the Investor Center section of Neuralstem's we... 
Download PDFPrinter Friendly Version
02/16/16Neuralstem Appoints Richard Daly as President and Chief Executive Officer
GERMANTOWN, Md., Feb. 16, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology, announced the appointment of Richard J. Daly to the position of President and Chief Executive Officer, effective February 15, 2016. Mr. Daly brings to the position over 25 years of commercial pharmaceutical leadership experience encompassing strategy, sales, marketing, and operations. ... 
Download PDFPrinter Friendly Version
01/27/16Neuralstem Presented Cell Therapy Update At Phacilitate Cell & Gene Therapy World Conference
NSI-566 Trial Data Reveals Biological Activity Across Multiple Neurodegenerative Diseases: ALS, Chronic Spinal Cord Injury, and Stroke GERMANTOWN, Md., Jan. 27, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop regenerative therapies and small molecule pharmaceutical drugs for CNS diseases and disorders, announced that Karl Johe, Ph.D., Neuralstem's Chairman and Chief Scientific Officer, provided an update on the c... 
Download PDFPrinter Friendly Version
01/06/16Neuralstem to Present at the Biotech Showcase 2016 Conference in San Francisco
GERMANTOWN, Md., Jan. 6, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that it will present at the Biotech Showcase 2016 on Tuesday, January 12, 2016.  The presentation is scheduled at 2:00PM PST, in the Parc 55 Hilton Hotel, San Francisco. A live audio webcast of the presentation will be available by visiting the Inv... 
Download PDFPrinter Friendly Version